In a Phase 2a study in patients with MELAS, zagociguat exhibited a favorable safety profile, exposure throughout the body including in the central nervous system, and improvements in neuronal function ...

3243A>G mitochondrial diseases," says Dr. Yahata. Overall, the study represents a significant advancement in mitochondrial ...

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted ...

Overall, the study represents a significant advancement in mitochondrial medicine for several reasons. First, it provides researchers with multiple isogenic—otherwise genetically identical ...